Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-azacytidine + trastuzumab
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of 5-azacytidine (also known as azacitidine), a hypomethylating agent and cytidine nucleoside analog, and trastuzumab, a humanized monoclonal antibody targeting the HER2/neu receptor. 5-azacytidine incorporates into DNA and RNA, inhibiting DNA methyltransferase activity, leading to hypomethylation of DNA and reactivation of silenced genes involved in tumor suppression. Trastuzumab binds to the extracellular domain of the HER2/neu receptor (receptor tyrosine-protein kinase erbB-2), inhibiting downstream signaling pathways that promote cell proliferation in HER2-overexpressing cancers. This combination is being explored for potential synergistic antitumor effects by combining epigenetic modulation with targeted immunotherapy.
- Other names
- 5-azacytidine and trastuzumabazacitidine + trastuzumab
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)
Beyond the preview
Go deeper on 5-azacytidine + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-azacytidine + trastuzumab.